Vaccine Type: Replicating Viral Vector
This vaccine may also be referred to as Brilife
This vaccine has reached Phase 3 trials.
About Trial Phases
This vaccine is not yet approved.
Total Enrollment: 550
Total Enrollment: 1,040
© 2021 McGill COVID19 Vaccine Tracker Team
Funding provided by the McGill University Interdisciplinary Initiative in Infection and Immunity (MI4)
This site is provided for informational purposes only based on publically available data.
Site Credits | Website Feedback Form